Levonorgestrel transdermal - Agile Therapeutics

Drug Profile

Levonorgestrel transdermal - Agile Therapeutics

Alternative Names: AG 890; AG 900; AG-1000; Progestin-only

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator Agile Therapeutics
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pregnancy

Most Recent Events

  • 14 Jun 2016 Agile Therapeutics has patent protection for Progestin-only patch in USA
  • 15 Mar 2016 Agile Therapeutics has patent protection for AG 890 in Australia, Japan, Russia and New Zealand (Agile Therapeutics, Form 10-K, march 2016)
  • 12 Feb 2015 Phase-I/II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top